Vital Signs - Desire to Control Costs Drives Usage of Topical Hemostats and Tissue Sealants

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on December 17, 2007, provides a strategic overview the Topical Hemostats and Tissue Sealants market. Additionally, a company spotlight is provided for Angiotech Pharmaceuticals, a specialty pharmaceutical and medical device company that develops, manufactures and markets advanced technologies and medical products for local diseases, complications associates with medical device implants, surgical interventions and acute injury. Reimbursement and regulatory news from the FDA is also provided for the week of December 3 - December 7, 2007.

Table of Contents

Vital Signs - Desire to Control Costs Drives Usage of Topical Hemostats and Tissue SealantsVital Signs: 17 December 2007This week's issue:




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 20-Nov-17

Region : North America

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.